Evidence map›Paper›PMID 31881245›Full record

ArticleBiochimica et biophysica acta. General subjects2020

Lyn regulates creatine uptake in an imatinib-resistant CML cell line.

Denis O Okumu, Lucas J Aponte-Collazo, Brian J Dewar, Nathan J Cox, Michael P East, Katherine Tech, Ian M McDonald, Andrey P Tikunov, Ekhson Holmuhamedov, Jeffrey M Macdonald and 1 more

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta. General subjects, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Denis O OkumuDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, United States of America; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Lucas J Aponte-CollazoDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, United States of America; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Brian J DewarDepartment of Biomedical Engineering, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Nathan J CoxDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Michael P EastDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, United States of America; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Katherine TechDepartment of Biomedical Engineering, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Ian M McDonaldDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, United States of America; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Andrey P TikunovDepartment of Biomedical Engineering, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Ekhson HolmuhamedovInstitute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Puschino 142292, Russian Federation.
Jeffrey M MacdonaldDepartment of Biomedical Engineering, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Lee M GravesDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, United States of America; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, United States of America. Electronic address: lmg@med.unc.edu.
University of North Carolina at Chapel Hill · USInstitute of Theoretical and Experimental Biophysics · RUUNC Lineberger Comprehensive Cancer Center

Funding

TOXICOLOGYT32ES007126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ILONA JASPERS, Bernard E. Weissman · 1985 to 2026
$13.0M
PREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIST32GM007040 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS, ROBERT A · 1985 to 2019
$6.0M
Human Enterohepatic Cell Model for Predictive ToxicologyR21GM075941 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MACDONALD, JEFFREY M. · 2006 to 2008
$1.0M
NIEHS NIH HHS T32 ES007126NIGMS NIH HHS R21 GM075941NIGMS NIH HHS T32 GM007040
6 · The paper itself

Abstract

backgroundImatinib mesylate (imatinib) is the first-line treatment for newly diagnosed chronic myeloid leukemia (CML) due to its remarkable hematologic and cytogenetic responses. We previously demonstrated that the imatinib-resistant CML cells (Myl-R) contained elevated Lyn activity and intracellular creatine pools compared to imatinib-sensitive Myl cells.

methodsStable isotope metabolic labeling, media creatine depletion, and Na

resultsInhibition of the Na

conclusionsThese data suggest that Lyn can affect creatine uptake through Lyn-dependent phosphorylation and regulation of the Na GENERAL SIGNIFICANCE: These studies identify kinase regulation of the Na

Indexed as

Antineoplastic AgentsCell ProliferationCell SurvivalCreatineDrug Resistance, NeoplasmDrug Screening Assays, AntitumorHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL Positivesrc-Family KinasesTumor Cells, CulturedAntineoplastic AgentsCreatineImatinib Mesylatelyn protein-tyrosine kinasesrc-Family Kinases(1)H NMR spectroscopyApoptosisCell viabilityChronic myelogenous leukemiaCreatineCreatine transporterCyclocreatineDrug resistanceImatinibKinaseLynMetabolitesMetabolomicsPhosphocreatinePonatinibSodium/potassium-ATPase

Identifiers

PMID31881245
PMCPMC7055176
OpenAlexW2996969565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.